Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 34c, Beats on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025 4:14 PM EDTCatalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook
Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase
FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength
Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 Million
Strengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025
Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET
CORAL GABLES,... More
